{"id":547534,"date":"2021-06-14T18:12:01","date_gmt":"2021-06-14T18:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=547534"},"modified":"2021-06-14T18:12:01","modified_gmt":"2021-06-14T18:12:01","slug":"new-therapeutics-options-for-vasomotor-symptoms-of-menopause-are-becoming-available-as-9-companies-are-working-on-drug-profiles","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/new-therapeutics-options-for-vasomotor-symptoms-of-menopause-are-becoming-available-as-9-companies-are-working-on-drug-profiles_547534.html","title":{"rendered":"New therapeutics options for Vasomotor Symptoms of Menopause are becoming available as 9+ companies are working on drug profiles"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623669001.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"New therapeutics options for Vasomotor Symptoms of Menopause are becoming available as 9+ companies are working on drug profiles\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623669001.png\" alt=\"New therapeutics options for Vasomotor Symptoms of Menopause are becoming available as 9+ companies are working on drug profiles\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Vasomotor Symptoms of Menopause Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Vasomotor Symptoms of Menopause Pipeline report from DelveInsight gives detailed insights about 9+ companies and 9+ pipeline therapies in the pipeline landscape for Vasomotor Symptoms of Menopause. It includes clinical and nonclinical stage products in the pipeline drug profiles.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/8aaa9720758d8724ef5ad1a6a548ea8d.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Vasomotor Symptoms of Menopause Pipeline report<\/a><\/strong> from DelveInsight gives detailed insights about 9+ companies and 9+ pipeline therapies in the pipeline landscape for Vasomotor Symptoms of Menopause. It includes clinical and nonclinical stage products in the pipeline drug profiles.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some Key Highlights from the Vasomotor Symptoms of Menopause Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">There are currently 9+ Vasomotor Symptoms of Menopause pipeline therapies in various stages of development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Fezolinetant and Estetrol oral tablet|Progesterone oral tablet<\/strong> are the pipeline therapies for Vasomotor Symptoms of Menopause which are currently in Phase III of clinical trials.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline therapy <strong>G-CSF<\/strong> for Vasomotor Symptoms of Menopause is in the early stage of development i.e. Phase I of clinical trials.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Some of the companies developing therapies for the treatment of Vasomotor Symptoms of Menopause are <strong>Astellas Pharma Inc, Estetra, MenoGeniX, Inc.,<\/strong> among others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">For more insights, request sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Vasomotor Symptoms of Menopause Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Vasomotor Symptoms of Menopause often known as hot flashes or flushes (HFs) and night sweats, are the most frequent menopausal symptoms for which women seek treatment. Changes in gonadal hormones cause Vasomotor Symptoms of Menopause, which is a type of temperature dysregulation.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Constriction or dilation of blood vessels causes Vasomotor Symptoms. Hot flashes and other symptoms may begin during perimenopause, while menstruation is still ongoing, or after a person&#8217;s periods have ended. Not everyone has these symptoms, and their severity varies from person to person.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause: Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hormone Therapy<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Hormone therapy seeks to bring the body&#8217;s hormone levels into balance. It can help with hot flashes and other symptoms, but it isn&#8217;t for everyone because it can have negative side effects. Hormone therapy, on the other hand, is not suggested for persons who have a history of or are at high risk of certain diseases, such as breast cancer, stroke, uterine cancer, or liver disease.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Antidepressant drugs<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Antidepressants like paroxetine (Paxil) may be beneficial. For menopause symptoms, a doctor will normally prescribe a lesser dosage than for depression. Headaches, nausea, and sleepiness are all possible side effects.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lifestyle Remedies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Avoiding known triggers and practicing deep breathing are two examples of lifestyle practices.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Fezolinetant: Astellas Pharma Inc.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Fezolinetant is a selective neurokinin-3 receptor (NK3R) antagonist that inhibits neurokinin B (NKB) binding to the kisspeptin\/neurokinin\/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory area of the hypothalamus to treat VMS associated with menopause.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Research and Development in the Vasomotor Symptoms of Menopause Pipeline Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase III Clinical Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT04234204:<\/strong> To assess the efficacy and safety of fezolinetant in Asian women suffering from moderate to severe vasomotor symptoms (Hot Flashes) associated with menopause, Astellas Pharma launched a phase III randomised, placebo-controlled, 12-week double-blind study, followed by a non-controlled extension treatment period. Fezolinetant (1 tablet) once a day or placebo (1 tablet) once a day are the trial treatments.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fezolinetant: Astellas Pharma Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Estetrol oral tablet|Progesterone oral tablet: Estetra<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">G-CSF: MenoGeniX, Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">To learn more, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Vasomotor Symptoms of Menopause Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause Therapeutics Assessment<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Combination Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discovery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-Clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase I<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase II<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase III<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-registration<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small Molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immune System<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease Inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulatory<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause Key Players:<\/strong> Astellas Pharma Inc, Estetra, MenoGeniX, Inc., among others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms of Menopause Pipeline Therapies:<\/strong> Fezolinetant, Estetrol oral tablet|Progesterone oral tablet, G-CSF,&nbsp; and others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"78\" \/>\n<col width=\"546\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause- Collaborations, Licensing, Acquisition &#8211; Deal Value Trends<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Collaboration Deals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause- Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause- Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Vasomotor Symptoms of Menopause Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Vasomotor Symptoms of Menopause Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the various treatment options for Vasomotor Symptoms of Menopause?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many companies are developing medications to treat menopausal vasomotor symptoms?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Which of these companies&#8217; medications is the most popular?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What is the total number of Vasomotor Symptoms of Menopause drugs that each company has produced?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many pipeline therapies for Vasomotor Symptoms of Menopause are in the early, mid, and late stages of development?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many of the therapies in development can be used on their own or in conjunction with other therapies?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licensure practises that influence Vasomotor Symptoms of Menopause?<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Postmenopausal Osteoporosis Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get comprehensive analysis of Postmenopausal Osteoporosis pipeline therapies and key companies including <strong>Teva Pharmaceutical, Eli Lilly and Company, HEXAL, Samsung Bioepis, Celltrion, Huons Co., Ltd., Luye Pharma, Haoma Medica,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=new-therapeutics-options-for-vasomotor-symptoms-of-menopause-are-becoming-available-as-9-companies-are-working-on-drug-profiles\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=new-therapeutics-options-for-vasomotor-symptoms-of-menopause-are-becoming-available-as-9-companies-are-working-on-drug-profiles\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vasomotor Symptoms of Menopause Pipeline The Vasomotor Symptoms of Menopause Pipeline report from DelveInsight gives detailed insights about 9+ companies and 9+ pipeline therapies in the pipeline landscape for Vasomotor Symptoms of Menopause. It includes clinical and nonclinical stage products &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/new-therapeutics-options-for-vasomotor-symptoms-of-menopause-are-becoming-available-as-9-companies-are-working-on-drug-profiles_547534.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-547534","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=547534"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=547534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=547534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=547534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}